Haufinyane tjena, Novo Nordisk e phatlalalitse ka molao tlaleho ea eona ea lichelete ea 2022. Lintlha li bontša hore thekiso eohle ea Novo Nordisk ka 2022 e tla fihla ho 176.954 limilione tse likete tsa Danish krone (US $ 24.994 limilione tse likete, phetoho ea sekhahla sa phapanyetsano e phatlalalitsoe tlalehong ea selemo, e tšoanang ka tlase), ho fihlela 26% selemo le selemo, phaello ea ts'ebetso e tla fihla ho 74.809 limilione tse likete tsa Danish krone. (US $ 10.566 limilione tse likete), ho nyoloha ka 28% selemo le selemo, 'me phaello ea kakaretso e tla ba 55.525 limilione tse likete tsa Danish krone (US $ 7.843 limilione tse likete), ho nyoloha ka 16% selemo le selemo. Ts'ebetso e khahla haholo.

Ts'ebetso e ikhethang ea Novo Nordisk e tsoa hokae? Karabo ke analogue ea GLP-1. Liphaepheng tsa sehlahisoa sa Novo Nordisk, lihlahisoa li ka aroloa ka mefuta e mene: li-analogues tsa GLP-1, insulin le li-analogues, lintlha tsa coagulation le lihomone tse ling tsa metabolic, ka thekiso ea 83.371 billion Danish krone ($ 11.176 billion, ntle le lisebelisoa tsa ho theola boima ba 'mele), 52.952 billion Danish krone ($7.479 bilione), 11.706 billion Danish krone ($1.653 billion) le 7.138 billion Danish krone ($1.008 billion), ka ho latellana. Har'a li-analogues tsa GLP-1, thekiso ea ente ea hypoglycemic ea Liraglutide e ntse e fokotseha selemo le selemo, atheSemaglutidee hohela mahlo haholo, ka thekiso e felletseng ea lidolara tse limilione tse likete tse 10.882 ka 2022.